Author: admin

TurbineX_generators Launches Inspiring YouTube Channel to Promote Philanthropy and Support Good Causes

TurbineXgenerators, a dynamic new YouTube channel dedicated to promoting philanthropy and social good, is thrilled to announce its mission to transform lives through charity. With over thirteen thousand subscribers and counting, TurbineXgenerators is committed to supporting humanitarian aid, volunteer services, and environmental clean-up projects worldwide. The channel not only highlights deserving causes but also offers viewers exciting opportunities to contribute to these efforts and win amazing prizes as a token of appreciation.

TurbineX_generators has already made substantial contributions to several noteworthy causes. Their latest video showcases a successful fundraising campaign for a local fire station to enhance its food drive program, ensuring that those in need have access to essential resources. You can watch the inspiring story unfold here: https://www.youtube.com/watch?v=rG7SJgXmroE.

In addition to supporting emergency services, TurbineX_generators extends its generosity to community hubs like the Saint Michael Parish Center and various pet charities. The channel’s ethos firmly believes that no charity is out of bounds. Big or small, every act of kindness can ignite positive change, making a meaningful impact on communities everywhere.

“We started TurbineXgenerators with the vision of creating a platform where charitable causes could meet global support,” said the founder of TurbineXgenerators. “Our goal is to show that philanthropy isn’t just about giving—it’s also about engaging communities, spreading awareness, and building bridges of hope and support.”

Through vibrant storytelling and a passion for positive change, TurbineX_generators encourages viewers to get involved. The channel not only showcases remarkable charitable initiatives but also holds fun contests and giveaways to reward viewers for their support. By subscribing and engaging with the content, audiences stand a chance to win exciting prizes while contributing to various humanitarian and environmental causes.

Some of the key areas of focus for TurbineX_generators include:

– Humanitarian Aid: Supporting essential services and providing aid to communities in need.

– Volunteer Services: Encouraging community involvement through volunteer opportunities that make a real difference.

– Environmental Clean-Up: Raising awareness and driving action towards protecting our planet.

TurbineX_generators believes in the power of community action and personal engagement in fostering a more equitable world. By shining a light on diverse causes and encouraging actively involved audiences, the channel aims to create a ripple effect of kindness and generosity.

For more information on how you can make a difference and join this movement of goodwill, visit TurbineX_generators on YouTube and explore the myriad of heartwarming stories and upcoming charity initiatives they have in store. Together, let’s make the world a better place, one small act of kindness at a time.

Please visit https://www.youtube.com/@turbinex_generators

Please follow TurbineX_generators on social media to stay updated with our latest initiatives and heartwarming stories. Your support is the wind beneath our wings as we soar towards a better tomorrow.

Media Contact
Company Name: TurbineX_generators
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.youtube.com/@turbinex_generators

Wishcompany Offering Massive Discounts During Black Friday and Cyber Monday Sales

Smart shoppers can snag premium skincare from Wishcompany brands at up to 70% off during the upcoming Black Friday and Cyber Monday sales. These Korean skincare and beauty products have recently become viral sensations, and dedicated customers can get authentic products at substantial discounts.

Fans of Korean beauty and skincare products can find some of the most popular selections at the lowest prices this year during Wishcompany’s Black Friday and Cyber Monday sales. With sales discounting products up to 70% off the retail price, now is the best time to buy some of the internet’s favorite beauty and skincare products.

Wishcompany is the parent to viral brands like I’M FROM, Dear, Klairs, and By Wishtrend. These brands have recently been stars on the TikTok Shop and steady bestsellers on retailers like Amazon and Brand Store.

I’M FROM is a popular Korean skincare brand known for its Rice Line and Mugwort Line products, which feature innovative fermentation technology, gentle low-pH formulas, glass skin radiance, and natural ingredients. During the sale, customers will find significant discounts on the brand’s bestsellers. 

The Rice Line will be represented during the sales with a 48% discount on Rice Toner ($15.99) and a 41% cut on Rice Cream ($17.99). Fans of the Mugwort Line can find Mugwort Essence at 50% off ($19.99) and Mugwort Cream for 39% off ($19.22). 

Dear, Klairs is a vegan-friendly, cruelty-free Korean skincare and beauty brand committed to eco-friendly practices and dedicated to developing clean and functional products that cater to all skin types. With a robust line of versatile products made from raw, natural ingredients, Dear, Klairs has secured its position in the competitive beauty market.

Savvy shoppers can buy the company’s viral Blue Drop night serum for 24% off ($22.80.) The popular Vitamin Drop antioxidant serum will be 45% off ($11.90). Fans of the brand’s Soothing Cream can get a bottle at 46% off during the sale ($13.99), and the Blue Calming Cream will be 45% off ($16.99.) For anyone who has seen these products go viral and wanted to try them, there has never been a better time to experience luxuriant Korean skincare at an affordable price.

By Wishtrend offers the latest K-Beauty trends and the finest in Korean skincare products. The brand is a trusted source of cruelty-free products that showcase customers’ natural beauty. It has recently gone viral for its anti-aging night cream.

The Vitamin A-mazing Bakuchiol Retinal Night Cream will be on sale at a stunning 70% off. Korean skincare fans can try this popular skin-smoothing, pore-refining cream for just $9.90 during the Black Friday and Cyber Monday sales. 

Visit the official Wishcompany website for more information about the biggest sale of the year or to make a purchase. Check out the significant discounts on each brand’s Amazon page for the year’s best deals on some of the most popular Korean skincare and beauty products on the market.

Media Contact
Company Name: Wishcompany
Contact Person: Aileen Hwang
Email: Send Email
Country: United States
Website: https://wishtrend.com

Roofing Guildford by Experts from Skylark Roofing for Installation and Repair of All Roof Types Backed by Reliable Customer Service

Roofing Guildford by Experts from Skylark Roofing for Installation and Repair of All Roof Types Backed by Reliable Customer Service
Founded by Bill Williams, Skylark Roofing is a locally owned family business that has earned the community’s trust through its expert roof installation and repair services. It approaches each job, big or small, with the same dedication to customer satisfaction.

According to announcements released by Skylark Roofing and Bill Williams, this roofing Guildford business provides premier roofing solutions for homeowners in Guildford and Surrey, ensuring high-quality craftsmanship and dependable service for all roofing needs. Recognizing that even minor roof damage can lead to significant issues if left unaddressed, Skylark Roofing offers comprehensive repair services designed to restore the integrity of roofs quickly and effectively. Whether addressing a few missing tiles, a minor leak, or storm-related damage, Skylark Roofing employs an experienced team adept at diagnosing many roofing concerns. The company ensures repairs that stand the test of time and protect homes from further complications by utilizing premium materials.

Specializing in new roof installations, Skylark Roofing tailors its services to Guildford and Surrey homeowners’ unique needs. A new roof represents a significant investment in a property’s protection, aesthetics, and value. Skylark Roofing’s team works precisely to deliver durable and visually appealing results. Offering a variety of materials, including traditional slate and tile, as well as modern alternatives, the company provides options to suit different architectural styles and budgets.

The installation begins with a detailed consultation, where Skylark Roofing assesses specific requirements and develops a customized plan. This meticulous approach, combined with a commitment to high-quality materials and expert craftsmanship, ensures that new roofs are designed to withstand the elements while enhancing property value. From the initial consultation to project completion, Skylark Roofing prioritizes a seamless and hassle-free experience for its clients.

For more information, go to https://roofingguildford.co.uk/

Flat roofing is another specialty service Skylark Roofing offers, providing reliable, long-lasting solutions for various structures, including extensions and garages. Flat roofs require a precise approach to installation and maintenance, with materials designed for durability, effective drainage, and weather resistance. With extensive experience across traditional and modern flat roofing systems, Skylark Roofing delivers exceptional results that balance functionality and style.

Every flat roof installed by Skylark Roofing is crafted to endure the challenges posed by the climate, ensuring cost-effective protection for years to come. The company’s expertise in flat roofing enables minimal installation disruption, focusing on delivering practical solutions that align with clients’ aesthetic preferences.

In addition to installation services, Skylark Roofing provides emergency roof repairs and preventative maintenance to protect homes from escalating damage. Swift action and attention to detail are hallmarks of the company’s repair services, ensuring homes remain safe, dry, and structurally sound. By addressing issues promptly, Skylark Roofing helps homeowners avoid costly long-term damage and maintain their roofs in excellent condition.

Fascia and soffit installation services are another area of expertise for Skylark Roofing, offering essential protection and a polished appearance for residential properties. Fascia and soffits are critical in safeguarding a roof’s structure by preventing moisture build-up and ensuring proper ventilation. Skylark Roofing uses durable, weather-resistant materials to provide long-lasting protection while enhancing the home’s overall aesthetic.

With various styles and colors available, Skylark Roofing ensures that fascia and soffit installations complement the property’s design. Attention to detail during installation ensures effective rainwater management and reduced maintenance requirements, making these services an excellent investment in both functionality and curb appeal.

Comprehensive guttering services round out Skylark Roofing’s offerings, protecting properties from water damage through installation, repair, and maintenance solutions. Clean and functional gutters are essential for directing rainwater away from a home’s foundation, preventing dampness, leaks, and erosion. Skylark Roofing provides affordable cleaning services in Guildford and durable gutter installations and repairs tailored to homeowners’ needs.

About the Company:

Skylark Roofing has been committed to delivering professional and reliable roofing services across Guildford and Surrey for over two decades. By focusing on excellent craftsmanship and personalized solutions, the company supports homeowners in safeguarding and enhancing their properties. From emergency repairs and new roof installations to specialized flat roofing and guttering services, Skylark Roofing continues to set a high standard in the roofing industry.

Media Contact
Company Name: Skylark Roofing
Contact Person: Bill Williams
Email: Send Email
Phone: 01483 677193
Address:8 Carthouse Cottages, Old Merrow Street
City: Guildford
State: GU4 7BB
Country: United Kingdom
Website: https://roofingguildford.co.uk

Sickle Cell Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer

The Key Sickle Cell Disease Companies in the market include – Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others.

 

DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom.

 

To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast

 

Some of the key facts of the Sickle Cell Disease Market Report: 

  • Amon the 6MM countries the Sickle Cell Disease market size was valued ~USD 650 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on transformative therapies for oncology and rare diseases, announced that initial results from a Phase 1 clinical trial of motixafortide—evaluated both as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)—will be presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, scheduled for December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, the proof-of-concept study aims to explore innovative HSC mobilization strategies that could enhance the treatment experience for SCD patients pursuing gene therapy.

  • In June 2024, Vertex Pharmaceuticals has shared long-term results for its gene therapy, Casgevy (exa-cel), in patients with sickle cell disease or transfusion-dependent beta-thalassemia (TDT).

  • In 2023, the United States held the largest market share for Sickle Cell Disease among the 6MM, with approximately USD 603 million, followed by France and the UK.

  • In May 2023, The experimental cell-based gene-editing therapy called EDIT-301, administered as a single infusion, received orphan drug designation from the US Food and Drug Administration (FDA) for treating sickle cell disease (SCD).

  • At present, treatments for Sickle Cell Disease include NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics. Additionally, the US FDA has approved several therapies for this condition, such as DROXIA (hydroxyurea), ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor).

  • In 2023, the United States had the largest total number of prevalent Sickle Cell Disease cases among the 6MM.

  • In the US, Sickle Cell Anemia (hemoglobin S/S or hemoglobin S/β0-thalassemia) was the most common subtype of Sickle Cell Disease among the type-specific prevalent cases in 2023.

  • In the EU4 and the UK, France had the highest prevalence of Sickle Cell Disease cases, followed by the UK, while Spain reported the lowest number of cases.

  • Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others 

  • Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

  • The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally

  • The Sickle Cell Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.

 

Sickle Cell Disease Overview

Sickle cell disease (SCD) comprises inherited red blood cell disorders resulting from an abnormality in the structure of hemoglobin known as sickle hemoglobin (HbS), which encodes the beta hemoglobin subunit.

 

Get a Free sample for the Sickle Cell Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/sickle-cell-disease-market

 

Sickle Cell Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Sickle Cell Disease Epidemiology Segmentation:

The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Sickle Cell Disease

  • Prevalent Cases of Sickle Cell Disease by severity

  • Gender-specific Prevalence of Sickle Cell Disease

  • Diagnosed Cases of Episodic and Chronic Sickle Cell Disease

 

Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiology Forecast

 

Sickle Cell Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sickle Cell Disease market or expected to get launched during the study period. The analysis covers Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sickle Cell Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Sickle Cell Disease Therapies and Key Companies

  • CASGEVY (exagamglogene autotemcel): Vertex Pharmaceuticals/CRISPR Therapeutics

  • ENDARI (L-glutamine): Emmaus Life Sciences

  • Mitapivat: Agios Pharmaceuticals

  • Inclacumab: Pfizer

  • GMI-1687: Glycomimetics

  • BIVV003: Sanofi

  • CSL889: CSL Behring

  • Siplizumab: ITB-Med LLC

  • Etavopivat Tablets: Novo Nordisk A/S

  • VIT-2763: Fortrea, Inc.

  • Crizanlizumab: Novartis

  • Epeleuton: Afimmune

  • Voxelotor: Pfizer

  • Hydroxycarbamide: ADDMEDICA SASA

  • Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals

  • Mitapivat: Agios Pharmaceuticals

  • Canakinumab: Novartis

  • ALXN1820: Alexion Pharmaceuticals

  • Crovalimab: Chugai Pharmaceutical/Roche

  • EDIT 301: Editas Medicine

  • BIVV003: Sangamo Therapeutics

  • BEAM101: Beam Therapeutics

  • Hemopexin: CSL Behring

 

Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease Treatment Landscape

 

Scope of the Sickle Cell Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)]

  • Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others

  • Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

  • Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies

  • Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Sickle Cell Disease Unmet Needs, KOL’s views, Analyst’s views, Sickle Cell Disease Market Access and Reimbursement 

 

To know more about Sickle Cell Disease companies working in the treatment market, visit @ Sickle Cell Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Sickle Cell Disease Market Report Introduction

2. Executive Summary for Sickle Cell Disease

3. SWOT analysis of Sickle Cell Disease

4. Sickle Cell Disease Patient Share (%) Overview at a Glance

5. Sickle Cell Disease Market Overview at a Glance

6. Sickle Cell Disease Disease Background and Overview

7. Sickle Cell Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Sickle Cell Disease 

9. Sickle Cell Disease Current Treatment and Medical Practices

10. Sickle Cell Disease Unmet Needs

11. Sickle Cell Disease Emerging Therapies

12. Sickle Cell Disease Market Outlook

13. Country-Wise Sickle Cell Disease Market Analysis (2020–2034)

14. Sickle Cell Disease Market Access and Reimbursement of Therapies

15. Sickle Cell Disease Market Drivers

16. Sickle Cell Disease Market Barriers

17.  Sickle Cell Disease Appendix

18. Sickle Cell Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/blog/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer

Why Wealth Broker Is the Top Choice for Reliable Online Trading in 2024

Wealth Broker’s internet brokerage application has undergone a comprehensive upgrade in the third quarter of this year, with its AI features standing out.

As the securities market continues to mature and investor demands grow, supported by technologies such as big data and cloud computing, brokerage-owned apps are constantly enhancing their intelligent and diversified online services. This evolution is reshaping the mobile securities ecosystem and layout, gradually becoming the primary means for investors to obtain financial information.

In this wave, Wealth Broker actively leverages its strong R&D capabilities, combining internet technology with financial technology to truly focus on user needs, safeguarding and enhancing the value of user assets.

Review of Wealth Broker’s AI Features

In the new App version released in the third quarter of this year, Wealth Broker has introduced AI news analysis, AI customer service, AI investment consulting, AI secretary, and IPO research report assistants, achieving technological innovation and user experience enhancement in multiple aspects.

1. AI News Analysis

Wealth Broker utilizes the latest data analysis and machine learning technologies to provide clients with market trend forecasting, investment portfolio optimization, and risk assessment services. Users can receive real-time market news on the app’s Square page, helping investors extract valuable information from massive market data, reducing information disparities, and improving investment efficiency.

2. AI Customer Service

A user-centric service philosophy is key for internet brokers to win the market and customers. In Desouls Square, Wealth Broker has introduced AI customer service “Zhaocai,” the mascot and customer service assistant of Wealth Broker, providing 24/7 service. No matter when and where users initiate a consultation, they can quickly receive a response, enhancing customer satisfaction and trust with its immediacy.

3. AI Investment Consulting

After obtaining information such as the client’s risk preferences and trading habits, Wealth Broker’s AI investment consulting function provides the optimal asset allocation portfolio through a series of calculations and model simulations. This includes providing advice on savings, investments, budgeting, and financial planning, answering questions about financial markets, investment tools, and economic trends, recommending investment and wealth management books, and helping investors clarify financial goals and provide strategies to achieve these goals, making investment advice more personalized and investor-oriented.

4. AI Secretary

In addition to displaying basic information about listed companies that users want to know— including financial reports, business updates, and market dynamics, and automatically answering common questions, the AI secretary can also act as a smart assistant in the daily work of investor relations staff, such as taking meeting minutes, gathering market information, writing press releases, and helping investor relations staff develop more effective communication strategies.

5. IPO Research Report Assistant

For investors, in-depth reading and analysis of research reports are crucial. The large number of research reports, slow manual reading efficiency, and lack of highlighted key information are pain points for many investors. Wealth Broker’s IPO research report assistant allows users to ask questions in natural language, helping users analyze and summarize research reports, saving the work of going through each report one by one. It extracts relevant data from the reports in response to specific user questions, helping users quickly grasp important information from the reports and improving efficiency.

It is reported that Wealth Broker has recently launched a million-share lottery event, which will run until the end of this year.

About Wealth Broker

Wealth Broker is a leading digital one-stop investment and wealth management platform headquartered in Singapore, holding brokerage financial qualifications issued by the Australian ASIC and New Zealand FSPR. Through its self-developed brokerage platform, it is committed to providing global individual investors with a full range of cross-border assets and wealth management products, including stocks, bonds, funds, and structured products. Its cooperative institutional clients cover various financial sectors such as commercial banks, securities firms, family offices, wealth management companies, and fund management companies.

Wealth Broker, leveraging internet innovation technology and financial engineering, relies on its strong R&D capabilities and technological innovation to adhere to the concept of “Simple and Safe.” It can achieve account opening, funding, and trading of Hong Kong and U.S. stocks within 10 minutes, dedicated to ensuring the security of customer assets and helping global end-users to preserve and increase the value of their assets.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Wealth Broker
Contact Person: Media Relations
Email: Send Email
City: NY
Country: United States
Website: https://www.wbroker.com/

San Diego Attorney Kenneth VanDerBeck Champions Community Support and Patient Advocacy through Legal Expertise

San Diego Attorney Kenneth VanDerBeck Champions Community Support and Patient Advocacy through Legal Expertise

Kenneth VanDerBeck, San Diego Attorney
Kenneth VanDerBeck uses his legal and medical background to champion healthcare rights and advocate for accessible community support.

Kenneth VanDerBeck, a dedicated attorney and advocate, is raising awareness about the importance of legal protection for patients and communities affected by healthcare-related issues. With a career rooted in integrity, empathy, and a background in medicine, Kenneth is passionate about addressing the gaps in healthcare rights and promoting justice for those in need.

“Healthcare isn’t just a medical issue—it’s a human rights issue,” says VanDerBeck. “Many people don’t realize that nearly 1 in 4 adults in the U.S. faces significant healthcare barriers due to cost, limited access, or lack of advocacy. That’s where legal intervention can make a huge difference.”

Kenneth’s experience working in the medical field has provided him with unique insights that he now applies to his legal practice, helping him connect deeply with clients and advocate effectively. He actively supports organizations like the Red Cross and Newbreak Church, believing that community involvement strengthens his ability to understand the concerns and needs of those he represents.

“Every day, I see the direct impact that healthcare inequality has on people’s lives,” VanDerBeck adds. “As a lawyer, my mission is to advocate for patients who feel overwhelmed by the system. Whether it’s ensuring access to necessary treatments or holding providers accountable, my goal is to give a voice to those who need it most.”

Studies show that over 50% of Americans report feeling confused or intimidated by the healthcare system, an issue VanDerBeck addresses by educating his clients and the public about their legal rights. By providing clear information and supporting local initiatives, he aims to empower individuals to navigate healthcare-related challenges confidently.

“Advocating for patient rights is about leveling the playing field,” VanDerBeck emphasizes. “People deserve to feel supported and understood, especially when it comes to their health. That’s why I’m committed to bridging the gap between healthcare and legal protection, so people can access the resources they need without unnecessary barriers.”

VanDerBeck encourages other attorneys and healthcare professionals to join him in supporting patient advocacy and reform. His message to aspiring lawyers and community members is simple: “Be there for your community. Engage with the issues that matter. Together, we can create meaningful change.”

About Kenneth VanDerBeck

Kenneth VanDerBeck is a San Diego-based attorney known for his commitment to justice, patient rights, and community involvement. With a unique background in medicine and a dedication to advocacy, he brings empathy and expertise to his legal practice. A University of Florida graduate, Kenneth actively volunteers with organizations like the Red Cross and Newbreak Church, embodying his values of compassion and service. He is passionate about ensuring that healthcare access and legal rights go hand in hand for those most in need.

Media Contact
Contact Person: Kenneth VanDerBeck
Email: Send Email
City: San Diego
State: California
Country: United States
Website: https://www.kennethvanderbeck.com/

Rheumatoid Arthritis Market Expected to Experience Major Growth by 2034, According to DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH

The Key Rheumatoid Arthritis Companies in the market include – Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others.

 

The Rheumatoid Arthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Rheumatoid Arthritis pipeline products will significantly revolutionize the Rheumatoid Arthritis market dynamics.  

 

DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Rheumatoid Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Rheumatoid Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Rheumatoid Arthritis Market Insight

 

Some of the key facts of the Rheumatoid Arthritis Market Report: 

  • The Rheumatoid Arthritis market size was valued approximately ~USD 29 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In July 2024, Navidea Biopharma has decided to discontinue its rheumatoid arthritis (RA) program following unsatisfactory findings from an exploratory analysis of the NAV3-33 trial. The Phase III study (NCT05246280), which included 523 participants, was designed to validate the use of intravenous (IV) Lymphoseek (Tc 99m tilmanocept) imaging in predicting clinical responses in RA patients starting anti-tumor necrosis factor alpha (TNFα) therapy.

  • In January 2024, Rise Therapeutics disclosed the enrollment of its initial participant in the Phase I clinical study of R-2487 for individuals diagnosed with rheumatoid arthritis.

  • In December 2023, MyMD Pharmaceuticals declared that the Investigational New Drug (IND) application for a Phase II clinical trial of oral MYMD-1 for rheumatoid arthritis treatment has received clearance from the US FDA. The company is currently preparing to commence the trial in the first quarter of 2024.

  • Rabeximod has the potential to become a viable treatment option in the rheumatoid arthritis market, as it directly targets a clinical gap by offering beneficial tolerability, a unique mechanism of action, and accessibility for both early and late stages of the disease.

  • As per the World Health Organization (2023), approximately 70% of individuals affected by rheumatoid arthritis are female, and 55% are aged 55 years or older.

  • The collective number of diagnosed prevalent cases of rheumatoid arthritis in the 7MM was estimated to be approximately 4,200,000 in 2023 and is anticipated to rise throughout the study duration.

  • In 2023, the United States reported the highest number of prevalent rheumatoid arthritis cases among the 7MM, with approximately 1,430,000 diagnoses. Additionally, this number is projected to rise throughout the forecast period.

  • In 2023, the age bracket of 55-64 years accounted for the highest number of cases, approximately 450,000, followed by the age group of 65 years and above in the United States.

  • Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others

  • Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others

  • The Rheumatoid Arthritis epidemiology based on gender analyzed that according to Pediatric Rheumatology prevalence rate is consistently higher in girls in comparison to boys

 

Rheumatoid Arthritis Overview

Rheumatoid Arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is the most common form of arthritis in children under the age of 16. It is a chronic autoimmune disease characterized by inflammation in the joints, which leads to pain, stiffness, swelling, and sometimes loss of joint function. 

 

Get a Free sample for the Rheumatoid Arthritis Market Report:

https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market

 

Rheumatoid Arthritis Market  

The dynamics of the Rheumatoid Arthritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.  

 

Rheumatoid Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Rheumatoid Arthritis Epidemiology Segmentation:

The Rheumatoid Arthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Rheumatoid Arthritis

  • Prevalent Cases of Rheumatoid Arthritis by severity

  • Gender-specific Prevalence of Rheumatoid Arthritis

  • Diagnosed Cases of Episodic and Chronic Rheumatoid Arthritis

 

Download the report to understand which factors are driving Rheumatoid Arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights

 

Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rheumatoid Arthritis market or expected to get launched during the study period. The analysis covers Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Rheumatoid Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Rheumatoid Arthritis Therapies and Key Companies

  • OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation

  • RINVOQ (upadacitinib): AbbVie

  • Rabeximod (Rob 803): Cyxone

  • Imvotamab: IGM Biosciences

  • Sarilumab (Kevzara): Regeneron/Sanofi

  • Baricitinib: Eli Lilly and Company

  • Certolizumab pegol: UCB BIOSCIENCES GmbH

  • Upadacitinib: AbbVie

  • Tofacitinib: Pfizer

  • Sarilumab SAR153191 (REGN88): Sanofi

  • GenaKumab: Changchun GeneScience Pharma

  • AIN457: Novartis

  • Etanercept: Istituto Giannina Gaslini

 

To know more about Rheumatoid Arthritis treatment, visit @ Rheumatoid Arthritis Medications

 

Rheumatoid Arthritis Market Drivers

  • Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Rheumatoid Arthritis

  • Population rates of social anxiety disorder in children and young people have been investigated in several countries

  • Many therapies are under investigation in various phases of clinical trials

 

Rheumatoid Arthritis Market Unmet Needs

  • Challenge in recognition of condition

  • Development of novel therapies

  • Limited availability in services

  • Poor disease understanding

  • Development of effective treatment

 

Scope of the Rheumatoid Arthritis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others

  • Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others

  • Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies

  • Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Rheumatoid Arthritis Unmet Needs, KOL’s views, Analyst’s views, Rheumatoid Arthritis Market Access and Reimbursement 

 

Discover more about therapies set to grab major Rheumatoid Arthritis market share @ Rheumatoid Arthritis market forecast

 

Table of Contents 

1. Rheumatoid Arthritis Market Report Introduction

2. Executive Summary for Rheumatoid Arthritis

3. SWOT analysis of Rheumatoid Arthritis

4. Rheumatoid Arthritis Patient Share (%) Overview at a Glance

5. Rheumatoid Arthritis Market Overview at a Glance

6. Rheumatoid Arthritis Disease Background and Overview

7. Rheumatoid Arthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Rheumatoid Arthritis 

9. Rheumatoid Arthritis Current Treatment and Medical Practices

10. Rheumatoid Arthritis Unmet Needs

11. Rheumatoid Arthritis Emerging Therapies

12. Rheumatoid Arthritis Market Outlook

13. Country-Wise Rheumatoid Arthritis Market Analysis (2020–2034)

14. Rheumatoid Arthritis Market Access and Reimbursement of Therapies

15. Rheumatoid Arthritis Market Drivers

16. Rheumatoid Arthritis Market Barriers

17.  Rheumatoid Arthritis Appendix

18. Rheumatoid Arthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/blog/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Market Expected to Experience Major Growth by 2034, According to DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH

SizeGenetics Launches the Ultimate Product for Wellness and Confidence Enhancement

“Sizegenetics Ultimate”

SizeGenetics, a leader in innovative wellness solutions, proudly announces the launch of its latest breakthrough product, SizeGenetics Ultimate. This cutting-edge device is designed to empower individuals with a new level of confidence, comfort, and improved quality of life through advanced design and technology.

The SizeGenetics Ultimate builds upon the brand’s renowned reputation for quality and safety. It features enhanced ergonomic designs, superior materials, and advanced functionality, ensuring an unparalleled experience for users. This new product continues SizeGenetics’ commitment to supporting health-conscious individuals who seek effective, non-invasive solutions to enhance their overall well-being.

Key Features of the SizeGenetics Ultimate Include:

  • Optimized Comfort Technology: Redesigned with soft padding and adaptable fittings to provide a comfortable experience for users of all sizes.
  • Improved Durability: Constructed with high-quality materials for long-lasting performance.
  • Advanced Adjustability: Incorporates a unique tension control system that allows for precise customization, catering to diverse individual preferences.
  • Easy-to-Use Design: Simplified assembly and user-friendly features make the Ultimate product accessible for both beginners and long-time users.

“Our mission at SizeGenetics is to create products that prioritize safety, effectiveness, and user satisfaction,” said Jes Bech Muller, CEO. “The Ultimate product represents the pinnacle of our research and development, offering an unmatched solution for individuals looking to boost their confidence and well-being.”

SizeGenetics has been a trusted name in the industry for over two decades, earning recognition for its commitment to customer satisfaction and product excellence. The launch of the SizeGenetics Ultimate reinforces the company’s dedication to innovation and its mission to positively impact lives.

Availability

The SizeGenetics Ultimate is now available for purchase on the brand’s official website (www.sizegenetics.com) and through authorized retailers.

About SizeGenetics

SizeGenetics is an FDA-cleared brand renowned for its high-quality products and customer-first approach. With a focus on enhancing individual well-being, SizeGenetics combines science-backed research and superior craftsmanship to deliver innovative solutions that promote confidence and improve quality of life.

For more information about the SizeGenetics Ultimate or other SizeGenetics products, visit www.sizegenetics.com

Media Contact
Company Name: Sizegenetics
Contact Person: Jes Bech Muller
Email: Send Email
Address:228 Park AVe S STE 300
City: New York
State: NY
Country: United States
Website: https://sizegenetics.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SizeGenetics Launches the Ultimate Product for Wellness and Confidence Enhancement

Protheragen Announces Vaccine Development Services Targeting Infectious Diseases

Protheragen is proud to release its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases.

Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. This strategic initiative aims to accelerate the creation of effective vaccines to combat emerging and re-emerging infectious threats.

Infectious diseases are disorders caused by organisms — such as bacteria, viruses, or parasites. A vaccine is a specialized biological formulation that triggers the immune system to recognize and activate protective responses against specific disease-causing agents. With the global landscape of infectious diseases continually evolving, vaccine development could be a feasible solution. However, creating vaccines for infectious diseases is a complex and demanding process that necessitates scientific knowledge, adherence to regulations, and thorough testing.

Protheragen focuses on delivering comprehensive vaccine development services, specifically designed to meet the distinct challenges presented by various pathogens. With advanced research equipment and an excellent expert team, the company can develop vaccines targeting different types of pathogens, including bacterial infections, fungal infections, viral infections, prion diseases, and parasitic infections. Utilizing system biology approaches, adjuvant, mRNA, and vector-based technologies, Protheragen provides mRNA vaccine, DNA vaccine, live-attenuated vaccine, virus-like particle vaccine, protein subunit vaccine, and many other custom vaccines.

Protheragen’s vaccine development services start with rigorous preclinical testing in order to assess the safety and efficacy of the vaccine candidates. After comprehensive preclinical evaluation, its expert team will explore whole pathogens, subunit antigens, and other sources to identify and characterize suitable antigens. Meanwhile, the team will employ advanced formulation techniques to optimize the delivery and presentation of antigens, ensuring enhanced immunogenicity and long-term protection. In the whole process of vaccine development, Protheragen ensures strict adherence to regulatory guidelines and industry standards.

The vaccine development services empower researchers and institutions with the tools and expertise needed to develop safe and effective vaccines efficiently. At the same time, these services position Protheragen as a leading infectious disease contract service provider in the biopharmaceutical landscape, committed to improving global health through innovative vaccine solutions.

About Protheragen

Protheragen is a research service provider providing one-stop services to support infectious disease-related research. From mechanism research and diagnostic development to therapeutic development, Protheragen’s comprehensive services are designed to meet the diverse needs of the infectious disease research landscape.

Media Contact
Company Name: Protheragen
Contact Person: Selina Green
Email: Send Email
Country: United States
Website: https://infectious.protheragen.us/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Protheragen Announces Vaccine Development Services Targeting Infectious Diseases

Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap

The Key Prurigo Nodularis Companies in the market include – Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others.

 

DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast

 

Some of the key facts of the Prurigo Nodularis Market Report: 

  • The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In August 2024, Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection to treat adults with prurigo nodularis. Nemluvio received Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024, highlighting its potential to significantly enhance treatment for serious conditions.

  • In March 2024, Incyte revealed recently released late-breaking data from a Phase II study assessing povorcitinib in individuals diagnosed with prurigo nodularis.

  • According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients.

  • In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis.

  • As per estimates, in Europe, the highest prevalence of age-specific cases of prurigo nodularis was observed in the 40-59 years age group, representing over 30% of the total cases in 2023.

  • DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development.

  • Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others

  • Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others

  • The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis

  • The Prurigo Nodularis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics.

 

Prurigo Nodularis Overview

Prurigo nodularis is a chronic skin condition characterized by the development of intensely itchy nodules or bumps on the skin. These nodules can vary in size and color and often appear on the arms, legs, or trunk. The itching associated with prurigo nodularis can be severe and persistent, leading to scratching and potentially causing further irritation and skin damage. The exact cause of prurigo nodularis is not fully understood, but it is believed to involve a combination of factors such as underlying skin conditions, nerve dysfunction, and immune system abnormalities. 

 

Get a Free sample for the Prurigo Nodularis Market Report 

https://www.delveinsight.com/report-store/prurigo-nodularis-market

 

Prurigo Nodularis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Prurigo Nodularis Epidemiology Segmentation:

The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Prurigo Nodularis

  • Prevalent Cases of Prurigo Nodularis by severity

  • Gender-specific Prevalence of Prurigo Nodularis

  • Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

 

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast

 

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Prurigo Nodularis Therapies and Key Companies

  • Nalbuphine ER: Trevi Therapeutics

  • Nemolizumab: Galderma

  • Vixarelimab(KPL-716): Genentech

  • Povorcitinib(INCB-54707): Incyte Corporation

  • Ruxolitinib Cream: Incyte Corporation

  • INCB054707: Incyte Corporation

  • serlopitant: Vyne Therapeutics Inc.

  • CC-10004: Celgene Corporation

  • Pimecrolimus: Novartis

  • Abrocitinib: Pfizer

  • Dupilumab SAR231893: Regeneron Pharma

 

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market

 

Prurigo Nodularis Market Strengths

  • Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options. 

  • Vixarelimab’s dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

 

Prurigo Nodularis Market Opportunities

  • Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market. 

  • Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies.

 

Scope of the Prurigo Nodularis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others

  • Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others

  • Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies

  • Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Prurigo Nodularis Unmet Needs, KOL’s views, Analyst’s views, Prurigo Nodularis Market Access and Reimbursement 

 

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Prurigo Nodularis Market Report Introduction

2. Executive Summary for Prurigo Nodularis

3. SWOT analysis of Prurigo Nodularis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis 

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Prurigo Nodularis Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2020–2034)

14. Prurigo Nodularis Market Access and Reimbursement of Therapies

15. Prurigo Nodularis Market Drivers

16. Prurigo Nodularis Market Barriers

17.  Prurigo Nodularis Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/blog/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap